Generex Biotechnology Corporation (NASDAQ: GNBT), a biopharmaceutical company, has a diversified product portfolio designed to deliver innovative products to treat patients with cancer. DNA/RNA-based Medicines and Small Molecules are the two major programs that anchor the Company’s research platform. Ganite® (gallium nitrate injection) is the company’s leading drug in the Small Molecule program. Ganite is exclusively marketed in the U.S. to treat symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. For further information, visit the Company’s web site at www.genta.com.
- 18 years ago
QualityStocks
Generex Biotechnology Corporation (NASDAQ: GNBT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks –Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) Working with ExploreTech to Conduct Data Review and Drill Optimization at the Schryburt Lake REE-Niobium Project
Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include…
-
QualityStocksNewsBreaks –From Pilot to Scale: Manufacturing Partnerships and Commercialization in Service Robotics
TechForce Robotics has partnered with NUWA Robotics and Foxconn to support the transition from pilot…
-
Earth Science Tech Inc. (ETST) Presents Fiscal Year-End Financial Results for March 31, 2026, Operating a Diversified Holding Company Model
Earth Science Tech Inc. (OTC: ETST) recently reported year-end financial results for the fiscal year…